Sophie Boucher

Sophie Boucher

Auto-generated profile, based on publicly available information

Sophie Boucher

Department of ear, nose, throat, University Hospital Center in Angers

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
Cedric AnnweilerCedric Annweiler
Cedric Annweiler
MBMélinda Beaudenon
Mélinda Beaudenon
JGJennifer Gautier
Jennifer Gautier
JGJustine Gonsard
Justine Gonsard
SBSophie Boucher
Sophie Boucher
OGon behalf of the COVIT-TRIAL study group
on behalf of the COVIT-TRIAL study group
Background: Vitamin D supplementation has been proposed as a treatment for Coronavirus Disease 2019 (COVID-19) based on experimental data and data from small and uncontrolled observational studies. The COvid19 and VITamin d TRIAL (COVIT-TRIAL) study was conducted to test whether a single oral high dose of cholecalciferol (vitamin D3) administered within 72 hours after the diagnosis of COVID-19 improves, compared to standard-dose cholecalciferol, the 14-day overall survival among at-risk older adults infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Methods and findings: This multicenter, randomized, controlled, open-label, superiority trial involved collaboration of 9 medical centers in France. Patients admitted to the hospital units or living in nursing homes adjacent to the investigator centers were eligible if they were ≥65 years, had SARS-CoV-2 infection of less than 3 days, and at least 1 COVID-19 worsening risk factor (among age ≥75 years, SpO2 ≤94%, or PaO2/FiO2≤300 mm Hg). Main noninclusion criteria were organ failure requiring ICU, SpO2 ≤92% despite 5 L/min oxygen, life expectancy 800 IU/day during the preceding month, and contraindications to vitamin D supplements. Eligible and consenting patients were randomly allocated to either a single oral high-dose (400,000 IU) or standard-dose (50,000 IU) cholecalciferol administered under medical supervision within 72 hours after the diagnosis of COVID-19. Participants and local study staff were not masked to the allocated treatment, but the Steering Committee and the Data and Safety Monitoring Board were masked to the randomization group and outcome data during the trial. The primary outcome was 14-day overall mortality. Between April 15 and December 17, 2020, of 1,207 patients who were assessed for eligibility in the COVIT-TRIAL study, 254 met eligibility criteria and formed the intention-to-treat population. The median age was 88 (IQR, 82 to 92) years, and 148 patients (58%) were women. Overall, 8 (6%) of 127 patients allocated to high-dose cholecalciferol, and 14 (11%) of 127 patients allocated to standard-dose cholecalciferol died within 14 days (adjusted hazard ratio = 0.39 [95% confidence interval [CI], 0.16 to 0.99],P= 0.049, after controlling for randomization strata [i.e., age, oxygen requirement, hospitalization, use of antibiotics, anti-infective drugs, and/or corticosteroids] and baseline imbalances in important prognostic factors [i.e., sex, ongoing cancers, profuse diarrhea, and delirium at baseline]). The number needed to treat for one person to benefit (NNTB) was 21 [NNTB 9 to ∞ to number needed to treat for one person to harm (NNTH) 46]. Apparent benefits were also found on 14-day mortality due to COVID-19 (7 (6%) deaths in high-dose group and 14 (11%) deaths in standard-dose group; adjusted hazard ratio = 0.33 [95% CI, 0.12 to 0.86],P= 0.02). The protective effect of the single oral high-dose administration was not sustained at 28 days (19 (15%) deaths in high-dose group and 21 (17%) deaths in standard-dose group; adjusted hazard ratio = 0.70 [95% CI, 0.36 to 1.36],P= 0.29). High-dose cholecalciferol did not result in more frequent adverse effects compared to the standard dose. The open-label design and limited study power are the main limitations of the study.Conclusions: In this randomized controlled trial (RCT), we observed that the early administration of high-dose versus standard-dose vitamin D3 to at-risk older patients with COVID-19 improved overall mortality at day 14. The effect was no longer observed after 28 days.Trial registration: ClinicalTrials.govNCT04344041.

23 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SBSophie Boucher
Sophie Boucher
FTFabienne Wong Jun Tai
Fabienne Wong Jun Tai
SDSedigheh Delmaghani
Sedigheh Delmaghani
ALAndrea Lelli
Andrea Lelli
ASAmrit Singh-Estivalet
Amrit Singh-Estivalet
CPChristine Petit
Christine Petit
Presbycusis, or age-related hearing loss (ARHL), is a major public health issue. About half the phenotypic variance has been attributed to genetic factors. Here, we assessed the contribution to presbycusis of ultrarare pathogenic variants, considered indicative of Mendelian forms. We focused on severe presbycusis without environmental or comorbidity risk factors and studied multiplex family age-related hearing loss (mARHL) and simplex/sporadic age-related hearing loss (sARHL) cases and controls with normal hearing by whole-exome sequencing. Ultrarare variants (allele frequency [AF] < 0.0001) of 35 genes responsible for autosomal dominant early-onset forms of deafness, predicted to be pathogenic, were detected in 25.7% of mARHL and 22.7% of sARHL cases vs. 7.5% of controls (P = 0.001); half were previously unknown (AF < 0.000002). MYO6, MYO7A, PTPRQ, and TECTA variants were present in 8.9% of ARHL cases but less than 1% of controls. Evidence for a causal role of variants in presbycusis was provided by pathogenicity prediction programs, documented haploinsufficiency, three-dimensional structure/function analyses, cell biology experiments, and reported early effects. We also established Tmc1N321I/+ mice, carrying the TMC1:p.(Asn327Ile) variant detected in an mARHL case, as a mouse model for a monogenic form of presbycusis. Deafness gene variants can thus result in a continuum of auditory phenotypes. Our findings demonstrate that the genetics of presbycusis is shaped by not only well-studied polygenic risk factors of small effect size revealed by common variants but also, ultrarare variants likely resulting in monogenic forms, thereby paving the way for treatment with emerging inner ear gene therapy. Significance Presbycusis, or age-related hearing loss, is a major public health issue and the principal potentially modifiable risk factor for dementia. It is caused by environmental factors and largely uncharacterized genetic factors. We compared DNA sequences across genomic coding regions between familial or sporadic cases of severe presbycusis and controls with normal hearing. The frequency of ultrarare predicted pathogenic variants in genes known to cause dominant early-onset forms of deafness was significantly higher in both familial and sporadic cases than in controls. Pathogenicity of many of these variants was established with complementary analyses. Ultrarare variants have a large effect size and are known to cause monogenic disorders. These findings open up possibilities for curing these forms of presbycusis by gene therapy.

21 October 2020 in medRxiv
Verified
Preprint
Open access
PDF file
VDVincent Dubee
Vincent Dubee
PRPierre Marie Roy
Pierre Marie Roy
BVBruno Vielle
Bruno Vielle
EPElsa Parot-Schinkel
Elsa Parot-Schinkel
OBOdile BLANCHET
Odile BLANCHET
AMAlain Mercat
Alain Mercat
Background: The efficacy of hydroxychloroquine in coronavirus disease 2019 (COVID-19) remains controversial. Methods: We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: age ≥75 years, age between 60 and 74 years, and presence of at least one comorbidity, or need for supplemental oxygen (≤3 L/min). Eligible patients were randomized in a 1:1 ratio to receive either 800mg hydroxychloroquine on Day 0 followed by 400mg per day for 8 days or a placebo. The primary endpoint was a composite of death or tracheal intubation within 14 days following randomization. Secondary endpoints included mortality and clinical evolution at Day 14 and 28, viral shedding at Day 5 and 10. Results: The trial was stopped after 250 patients were included due to a slowdown of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and hydroxychloroquine groups, respectively. The median age was 77 years and 151 patients required oxygen therapy. The primary endpoint occurred in nine patients in the hydroxychloroquine group and eight patients in the placebo group (relative risk 1.12; 95% confidence interval 0.45– 2.80; P=0.82). No difference was observed between the two groups in any of the secondary endpoints. Conclusion: In this trial involving mainly older patients with mild-to-moderate COVID-19, patients treated with hydroxychloroquine did not experience better clinical or virological outcomes than those receiving the placebo.

14 February 2023 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
ATAntoine Teplitxky
Antoine Teplitxky
JGJennifer Gautier
Jennifer Gautier
MLMarion Lievre
Marion Lievre
GDGuillaume Duval
Guillaume Duval
CACédric Annweiler
Cédric Annweiler
SBSophie Boucher
Sophie Boucher

30 May 2022 in Surgery in Practice and Science
Verified
Journal Article
Open access
FSFrançoise Schmitt
Françoise Schmitt
EEEmilie Eyssartier
Emilie Eyssartier
MSMarine Sarfati-Lebreton
Marine Sarfati-Lebreton
LRLouis Rony
Louis Rony
SBSophie Boucher
Sophie Boucher
LMLudovic Martin
Ludovic Martin
To evaluate the impact of a bootcamp for new residents in surgery, in terms of both knowledge and skills improvement and psychological support. Prospective inclusion of all the 59 new residents in surgery from 2018 to 2020. Analysis of their perception of the training and comparison of the bootcamp and control groups (n = 9, including the residents who could not attend the bootcamp) with respect to the results of their skills evaluations and surgical knowledge. A two-day bootcamp is organized every year in October since 2013 at the All'Sims simulation center (University Hospital, Angers, France) just before the beginning of the internship. A subsequent skills evaluation takes place partly in the operating room and partly as an objective structured clinical examination (OSCE). New residents from the different surgical specialties and gynecology, after having given their written consent. Among the 50 residents who attended the bootcamp, knowledge in surgical skills improved by 10% (p<0.001). The median skills score on each OSCE station was at least one point higher in the bootcamp group than in the control group, predominantly in the suturing task (13.9+/-3.0 vs 11.5 +/- 1.6, p = 0.03). The reported usefulness level of the different surgical skills training when evaluated in consideration of daily practice varied from 50% to 95%. Feelings of ease and competency were quite well correlated with the reported usefulness of a given skill, especially since the task was a more generic one. Preparatory courses are of great interest for all surgical specialties as they improve procedural skills and knowledge as well as self-confidence during the first weeks of a resident's internship. As medical training continues to vary significantly between the different universities, such surgical curricula should be developed at a national level to standardize the surgical level of all new residents

27 December 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
AZAlban Ziegler
Alban Ziegler
ADAnne-Sophie Denommé-Pichon
Anne-Sophie Denommé-Pichon
SBSophie Boucher
Sophie Boucher
NBNathalie Bouzamondo
Nathalie Bouzamondo
ECEstelle Colin
Estelle Colin
DBDominique Bonneau
Dominique Bonneau